grant
Noncanonical activities of SETD7 in preventing prostate cancer progression andtherapy resistance
Organization UNIVERSITY OF MASSACHUSETTS BOSTONLocation BOSTON, UNITED STATESPosted 5 Dec 2024Deadline 30 Nov 2029
NIHUS FederalResearch GrantFY2025AOF2Androgen ReceptorAutomobile DrivingBET bromodomain inhibitorBET inhibitorBETiBasal Transcription FactorBasal transcription factor genesBindingBromodomain and Extra-Terminal motif inhibitorBromodomains and extra-terminal domain inhibitorCancer PatientCancer TreatmentCancerousCancersCell Communication and SignalingCell LineCell SignalingCellLineChromatinChromatin StructureClinicalClinical TrialsDevelopmentEC 2.1.1ENX-1EZH1EZH2EZH2 geneEndocrine TherapyEnhancer of Zeste 2 Polycomb Repressive Complex 2 SubunitEnhancersEnzyme GeneEnzymesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFoundationsGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenesGenetic TranscriptionGoalsGrowthHeterograftHeterologous TransplantationHistone-Lysine MethyltransferaseHistone-Lysine N-MethyltransferaseHistonesHormonal TherapyIntracellular Communication and SignalingKDM1AKDM1A geneKMT6KMT6AL-LysineLSD1LysineLysine-Specific Demethylase 1Lysine-Specific Demethylase 1AMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatingMethylationMethyltransferaseMolecular InteractionOncogenicOutcomePDX modelPatient derived xenograftPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPeptidesPlayProstate CAProstate CA PreventionProstate CancerProstate NeoplasmsProstate TumorProstate malignancyProstatic NeoplasiaProstatic NeoplasmsProtein Lysine MethyltransferaseProtein Methylase IIIProtein Methyltransferase IIIProteinsPublishingRNA ExpressionReceptor SignalingRegulationReportingResearchResearch SpecimenResistanceResistance developmentResistant developmentRoleSignal TransductionSignal Transduction SystemsSignalingSpecimenStrains Cell LinesTherapeuticTissue GrowthTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTranslatingTumor Suppressor ProteinsXenograftXenograft procedureXenotransplantationadvanced prostate cancerandrogen ablation therapyandrogen blockade therapyandrogen deprivation therapyandrogen deprivation treatmentandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate canceranti-cancer therapyassess effectivenessbiological signal transductionbromodomain extra-terminal inhibitorcancer progressioncancer therapycancer-directed therapycastration resistant CaPcastration resistant PCacastration resistant prostate cancercultured cell linedemethylationdesigndesigningdetermine effectivenessdevelop therapydeveloping resistancedevelopmentaldrivingeffectiveness assessmenteffectiveness evaluationepigenetic therapyepigeneticallyevaluate effectivenessexamine effectivenesshistone methylationhormone refractory prostate cancerhormone therapyinhibitorintervention designintervention developmentmalignancymethylaseneoplasm progressionneoplasm/cancerneoplastic progressionontogenypatient derived xenograft modelpatient oriented outcomespreventprevent prostate cancerpreventingprogramsprostate cancer cellprostate cancer modelprostate cancer preventionprostate cancer progressionprostate cancer resistant to androgenprostate tumor cellprostate tumor modelprotein expressionrefractory cancerresistance to therapyresistantresistant cancerresistant to therapysocial roletherapeutic resistancetherapy designtherapy developmenttherapy resistanttranscription factortranscriptional reprogrammingtransmethylasetreatment designtreatment developmenttreatment resistancetreatment strategytumortumor progressiontumor suppressorxeno-transplantxeno-transplantation
Description preview
PROJECT SUMMARY
Background: Epigenetic dysregulation involving lysine methyltransferases and demethylases play a critical role
in the progression of prostate cancer (PCa) and its resistance to androgen deprivation therapies (ADT) and
androgen receptor signaling inhibition therapies (ARSi). Our prior research has demonstrated that LSD1
promotes…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click